The Placebo Response Rate in Irritable Bowel Syndrome and Inflammatory Bowel Disease
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
The placebo response is the efficacy attributable to a treatment that is thought to have no specific pharmacologic effect on the condition being treated. Although potentially helpful in clinical practice, high and unpredictable placebo response rates present a major impediment to the success of clinical trials in inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Diverse factors contribute to the placebo response rates observed in clinical trials. These include patient characteristics, physician factors, frequency of study visits, characteristics of the outcome measures, concomitant treatments, regression to the mean, properties of the intervention and treatment setting, timing of the primary endpoint and natural history of the condition. Measures that may minimize the placebo response in IBD clinical trials include early timing of the primary endpoint, minimizing the number of study visits, restricting the patient population to those with documented inflammation (such as elevated biomarkers of inflammation or evidence of mucosal inflammation), including patients with more severe symptoms (i.e. greater disease activity) and enrolling patients with prior failure of immune modulators or biologics. Attempts to limit the placebo response in IBS studies have proven more difficult. Factors associated with higher placebo response rates in IBS studies include longer duration of treatment, greater number of office visits, frequency of administration of study intervention and overall treatment effect of the active agent under study. In the future, improved understanding of the factors that drive the placebo response rate should lead to more efficient study design and drug development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently pharmacologic therapy of IBS beyond symptomatic treatment for constipation or diarrhea remains unsatisfactory, as few studies have demonstrated an effectiveness of available treatments over placebo effects(13-18).”
From Randomised clinical trial: Symptoms of the irritable bowel syndrome are improved by a psycho-education group intervention (2013) · cites this paper as [14]
Citations
Cites
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634 · cited 1×
“The ability of the human body to respond to inert stimuli in a positive fashion has long been recognized in Western medicine. A placebo is defined as a therapy being given for a specific condition without any specific known activity for that condition. Although useful in the practice of medicine, in which physicians r…”
BackgroundDevelopment of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147
Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026 · cited 1×
“In general, indices that do not incorporate sigmoidoscopy appear to correlate well with those that do. In recent years, the de facto choice for clinical activity index in ulcerative colitis trials has been the Mayo Score [”
BackgroundIs the Placebo Powerless?: An Analysis of Clinical Trials Comparing Placebo with No Treatment
Hróbjartsson, A., & Gøtzsche, P. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442106 · Cited by 1,503
D’Haens, G., Sandborn, W. J., Feagan, B. G., Geboes, K., Hanauer, S. B., Irvine, E. J., Lémann, M., Marteau, P., Rutgeerts, P., Schölmerich, J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.12.038 · Cited by 1,207 · cited 1×
“In this study, the primary analysis was confined to patients with elevated C-reactive protein ≥10 mg/l at baseline. At week 26, the response and remission rates were virtually identical for the high C-reactive protein population and for the full intent to treat population (all treated patients). Despite this failure t…”
Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome
Kaptchuk, T. J., Kelley, J. M., Conboy, L. A., Davis, R. B., Kerr, C. E., Jacobson, E. E., Kirsch, I., Schyner, R. N., Nam, B. H., Nguyen, L. T., et al. (2008) · BMJ · doi:10.1136/bmj.39524.439618.25 · Cited by 1,196 · cited 1×
“Although the placebo response rates in CAM trials of IBS were high, it was noted that the magnitude of the placebo response rate in these studies was quite similar to that seen in studies of conventional medications. It is worth noting that each of these meta-analyses adopted the practice common in IBS studies of defi…”
ResultMaintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,043 · cited 1×
“The primary endpoint was clinical response at week 12, defined as a decrease in the CDAI of ≥100 points from baseline or a CDAI of ≤150 points. At week 2, the placebo response rate was 15p, while the treatment arms had response rates ranging from 30 to 33p. These results were statistically significant. However, by wee…”
Kaptchuk, T. J. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-11-200206040-00011 · Cited by 616
Schreiber, S., Rutgeerts, P., Fedorak, R. N., Khaliq–Kareemi, M., Kamm, M. A., Boivin, M., Bernstein, C. N., Staun, M., Thomsen, O. Ø., & Innes, A. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.064 · Cited by 580
Research works printed but not linked: 1
- 10.1001%2fjama.273.5.408 · doi:10.1001/jama.273.5.408
Cited by
Biomarkers in inflammatory bowel disease: current practices and recent advances.
Iskandar, H. N., & Ciorba, M. A. (2012) · Translational Research · doi:10.1016/j.trsl.2012.01.001 · Cited by 210
“IBS type symptoms may account for the high placebo responses sometimes seen with CDAI use in trials.(10, 11) These high placebo rates lead to difficulty in demonstrating treatment efficacy, as evidenced by a recent trial of certolizumab in CD, where the use of biomarkers as objective measures of disease activity may h…”
BackgroundGupta, S. K., Vitanza, J. M., & Collins, M. H. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.05.021 · Cited by 191
Harper, J. W., D, M. N. S. M., & Zisman, T. L. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e31829cf401 · Cited by 175
“This phenomenon is reflected by the typically high placebo response rates in most IBD therapeutic trials.(27) We attempted to account for this by only considering objective measures of IBD activity, reflected by events such as surgery, hospitalization, or corticosteroid use.”
BackgroundMurine Models of Inflammatory Bowel Disease (IBD): Challenges of Modeling Human Disease
DeVoss, J., & Diehl, L. J. (2013) · Toxicologic Pathology · doi:10.1177/0192623313509729 · Cited by 89
“These variables are believed to be significant contributors to high placebo rates, which can obscure therapeutic benefits of drug candidates (Su et al. 2004; Sands et al. 2005; Sands 2009; D’Haens et al. 2012).”
Labus, J., Gupta, A., Gill, H. K., Posserud, I., Mayer, M., Raeen, H., Bolus, R., Simren, M., Naliboff, B. D., & Mayer, E. A. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12171 · Cited by 64
Metadata
- Authors
- Sands, B. E.
- Affiliations
- Harvard University (US)
- Corresponding author
- Sands, Bruce E.
- ORCID
- Sands, Bruce E.
- Venue
- Digestive Diseases
- Publisher
- S. Karger AG
- Published
- 2009
- Volume
- 27
- Issue
- Suppl. 1
- Pages
- 68-75
- ISSN
- 0257-2753 (ISSN-L)
- 1421-9875
- OpenAlex
- W1990410520
- Semantic Scholar
- 107b188b439229dd67d2dbb655a131da07aaad36
- Cited by
- 17
- References
- 23
- Citations by year
- 2022: 1 · 2021: 1 · 2019: 1 · 2018: 1 · 2016: 1 · 2015: 1 · 2014: 3 · 2013: 2 · 2012: 4
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Digestive Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- placebo response, irritable bowel syndrome, inflammatory bowel disease, clinical trial design, regression to the mean, biomarkers of inflammation, mucosal inflammation, immunomodulators, biologics, treatment duration
- MeSH terms
- Colitis, Ulcerative, Crohn Disease, Humans, Placebos, Inflammatory Bowel Diseases, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Placebo Response Rate in Irritable Bowel Syndrome and Inflammatory Bowel Disease. https://app.cochat.ai/papers/10.1159/000268123
- The paper
- Sands, B. E. (2009). The Placebo Response Rate in Irritable Bowel Syndrome and Inflammatory Bowel Disease. Digestive Diseases. https://doi.org/10.1159/000268123
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.